{"config":{"lang":["en"],"separator":"[\\s\\u200b\\-_,:!=\\[\\]()\"`/]+|\\.(?!\\d)|&[lg]t;|(?!\\b)(?=[A-Z][a-z])","pipeline":["stopWordFilter"]},"docs":[{"location":"","title":"My Detailed Documentation","text":""},{"location":"#introduction","title":"Introduction","text":"<p>Hello! My name is Yersultan. Welcome to my documentation page for my PhD projects in pharmacometrics at FU Berlin. This portal is my digital notebook, capturing my work, its challenges, and possible solutions.</p>"},{"location":"#documentation-goals","title":"Documentation Goals","text":"<p>This documentation serves multiple purposes:</p> <ul> <li>To document current knowledge of my projects<ul> <li>by reviewing articles and making notes from publicly available information.</li> </ul> </li> <li>To detail the technical aspects of my work,<ul> <li>by including pipelines for data curation and data processing.</li> <li>by including code snippets, libraries, and frameworks essential to my work</li> </ul> </li> <li>To ensure reproducibility <ul> <li>by providing some methodologies, codes, and troubleshooting strategies, </li> <li>by enabling me or anyone else to replicate the task.</li> </ul> </li> <li>To facilitate collaboration <ul> <li>by sharing knowledge and insights with team members and the broader research community.</li> </ul> </li> </ul>"},{"location":"#what-you-can-find-here","title":"What you can find here?","text":"<ul> <li>Literature review</li> <li>My notes about NLMEM</li> <li>Programming and Tools: </li> </ul>"},{"location":"#who-can-use-this","title":"Who can use this?","text":"<p>Whether you're a fellow researcher, a new team member, or just curious about pharmacometrics, this documentation is designed to provide you with a clear understanding of my work.</p> <p>Feel free to reach out if you have questions or would like to discuss. You can find me here </p> <ul> <li>FU Berlin \ud83d\udd17 </li> <li>LinkdIn profile \ud83d\udd17</li> <li>Email address \ud83d\udd17</li> </ul>"},{"location":"#acknowledgments","title":"Acknowledgments","text":"<p>This website was adapted from the work of Nima Chamyani and his documentation. </p>"},{"location":"exp/","title":"Experiments with Github Pages","text":"<ul> <li>Includes some functionalities that could be potentially used.</li> </ul>"},{"location":"exp/#creating-emoji-links-with-annotation","title":"creating emoji links with annotation","text":"<ul> <li>\ud83d\udd17</li> </ul>"},{"location":"Literature/","title":"Description","text":"<p>This section reflects my literature review for HydroCortisone Projects (HCP) and serves as a living document that will evolve over time. Here, you'll find insights, summaries, and key takeaways from various research articles and papers, particularly focusing on: </p> <ul> <li>Congenital adrenal hyperplasia (CAH);</li> <li>System components of cortisol regulation; </li> <li>Hormonal therapy with hydrocortisone;</li> <li>Information and description from clinical trials.</li> </ul>"},{"location":"Literature/CAH/","title":"Congenital Adrenal Hyperplasia","text":""},{"location":"Literature/CAH/#description","title":"Description","text":"<ul> <li>Group of inherited genetic disorders leading to impaired steroidogenesis<ul> <li>Presence of adrenal glands </li> <li>Absence of adequate cortisol synthesis</li> </ul> </li> <li> <p>adrenal insufficiency by dysfunction of </p> <ul> <li>adrenal gland (primary) </li> <li>pituitary gland (secondary)</li> </ul> </li> <li> <p>21-hydroxylase deficiency (Classic form) </p> <ul> <li>Most common (&gt;90%) [2003_Speiser]</li> <li>autosomal-recessive disorder</li> <li>chromosome 6p21.3</li> <li>mutation in CYP21A2</li> </ul> </li> </ul>"},{"location":"Literature/CAH/#classification","title":"Classification","text":"<ul> <li>Classic form <ul> <li>severe form: 0-5% enzyme activity</li> <li>deficiency of cortisol, aldosterone and adrenaline and overproduction of adrenal androgens [Claahsen-van der Grinten]</li> <li>Low intra-adrenal levels of cortisol -&gt; adrenomedullary dysplasia -&gt; deficiency in adrenalin [2000_Merke]</li> <li>salt wasters (75%):  <ul> <li>0% enzyme activity</li> <li>deficiency in cortisol and aldosterone synthesis [2000_White]</li> </ul> </li> <li>simple virilisers: <ul> <li>&lt;5% enzyme activity</li> <li>elevated concentrations of androgens [2003_Speiser]</li> <li>some ability to produce aldosterone </li> </ul> </li> <li>Prevalence<ul> <li>1:15,000-16,000 in Europe and the USA [2004_vanderKamp] </li> <li>1:19,000 in Japan [2004_vanderKamp]</li> <li>1:14,000-18,000 worldwide [Claahsen-van der Grinten]</li> </ul> </li> </ul> </li> <li>Non-classic form: <ul> <li>20-50% enzyme activity</li> <li>slightly elevated androgen concentrations</li> <li>Prevalence<ul> <li>1:200 in the USA [2017_Hannah-Shmoun]</li> <li>4.0\u20137.5% Carrier frequency in Europe [2005_Ezquieta] [2013_Phedonos] [2004_Baumgartner-Parzer]</li> </ul> </li> </ul> </li> </ul>"},{"location":"Literature/CAH/#genetic-background","title":"Genetic background","text":"<p>Figure from 2003_Speiser.</p>"},{"location":"Literature/CAH/#available-treatment-approaches","title":"Available treatment approaches","text":"<ul> <li>management of CAH should account for biological effects and interrelationship between glucocorticoid, mineralocorticoid and adrenal steroids</li> </ul>"},{"location":"Literature/CAH/#glucocorticoid-therapy","title":"Glucocorticoid therapy","text":"<ul> <li>re-set hormonal imbalance by replacing deficient hormones</li> <li>fail to replicate the physiological cortisol circadian rhythm</li> <li>usually supraphysiological doses to achieve sufficient reduction in androgen biosynthesis</li> <li>formulations<ul> <li>short-acting: Hydrocortisone<ul> <li>6\u20138 h </li> <li>preferred in children with CAH: short half-life and the lowest growth suppressing effect [2018_Speiser] [2007_Bonfig]</li> </ul> </li> <li>intermediate-acting: Prednisone, Prednisolone, Methylprednisolone<ul> <li>12\u201336 h </li> </ul> </li> <li>long-acting: Dexamethasone<ul> <li>36\u201354 h </li> </ul> </li> </ul> </li> <li>1/3 of adults receive hydrocortisone and 2/3 long-acting glucocorticoids<ul> <li>UK cross-sectional CAH adult study (CaHASE) from 17 centres (n = 203) [2010_Artl]</li> <li>cross-sectional study from our USA centre (n = 244) [2012_Finkielstain]</li> </ul> </li> </ul>"},{"location":"Literature/CAH/#mineralocorticoid-therapy","title":"Mineralocorticoid therapy","text":"<ul> <li>to correct aldosterone deficiency</li> <li>small enzyme activity and aldosterone production is not sufficient to maintain normal intravascular volume [2001_Frisch] [2006_Nimkarn]</li> <li>therapy received during childhood ~&gt; a taller height outcome compared when not received [2010_Muthusamy]</li> <li>formulation<ul> <li>9\u03b1-fludrocortisone<ul> <li>18\u201336 h</li> <li>risk factor of hypertension in children aged &lt;8 years [2015_Bonfig] [2021_Torky]</li> <li>adolescents have reduced (18.5% -&gt; 4.9%) risk of hypertension </li> </ul> </li> <li>All glucocorticoids (except dexamethasone) have mineralocorticoid activity<ul> <li>potency of 0.1 mg of fludrocortisone is achieved by ~40 mg of hydrocortisone [1955_Thorn]</li> <li>potency of 1.0 mg of hydrocortisone is achieved by 0.1 mg of fludrocortisone [2013_Liu]</li> </ul> </li> </ul> </li> </ul> <p>List if works used for literature review - [2022_Mallappa]</p>"},{"location":"Literature/clinical_trials/","title":"Clinical Trials","text":""},{"location":"Literature/clinical_trials/#reported-by-2015_whitaker","title":"Reported by 2015_Whitaker","text":"<ul> <li>[2015_Whitaker]<ul> <li>EudraCT number: 2013-000260-28</li> <li>NCT02777268</li> <li>Phase 1 Trial</li> <li>Healthy male volunteers<ul> <li>18-60 years</li> <li>no clinically significant sensitivity to hydrocortisone</li> <li>no clinically significant sensitivity to dexamethasone (DEX)  </li> <li>no infection</li> </ul> </li> <li>performed at Simbec Research Ltd (Merthyr Tydfil, UK)</li> </ul> </li> <li>Formulation: Infacort\u00ae (Diurnal Ltd)</li> <li>administration of HC (08:00 and 13:00)<ul> <li>after which received standardised meals</li> </ul> </li> <li>four study periods<ul> <li>n=16<ul> <li>2 volunteers were excluded <ul> <li>insufficient suppression of the HPA axis</li> </ul> </li> <li>median values with range<ul> <li>\\(age\\) 43.5 (21.0-59.0) years</li> <li>\\(body weight\\) 81.6 (64.7-96.0) kg</li> <li>\\(height\\) 1.77 (1.64-1.95) m</li> </ul> </li> </ul> </li> <li>DEX<ul> <li>1 mg </li> <li>in each study period</li> <li>to suppress the endogenous cortisol synthesis</li> </ul> </li> <li>Single morning oral (po) doses of Infacort\u00ae<ul> <li>0.5 mg </li> <li>2   mg</li> <li>5   mg</li> <li>10  mg </li> </ul> </li> <li>Washout period <ul> <li>at least 1 week between periods</li> </ul> </li> <li>Measurements<ul> <li>Total plasma cortisol concentrations (\\(C_{tot}\\))<ul> <li>every 0.5 h between [0 h, 8 h] </li> <li>every 1.0 h between [9 h, 12 h]</li> <li>LC-MS/MS</li> <li>Applied Biosystems MDS Sciex API 365 triple quadrupole atmospheric pressure ionisation mass spectrometer</li> <li>LLOQ 1.38 nmol/L</li> <li>intra-assay variability &lt;15% at LLOQ and &lt;10% for 22\u2013552 nmol/L</li> </ul> </li> </ul> </li> </ul> </li> </ul> <p>Summary of study design of the clinical trial. Figure was adopted from 2018_Melin.</p>"},{"location":"Literature/clinical_trials/#reported-by-2016_debono","title":"Reported by 2016_Debono","text":"<ul> <li>[2016_Debono]<ul> <li>EudraCT number: 2013-000259-42</li> <li>NCT01960530</li> <li>Phase 1 Trial</li> <li>included evaluation of the endogenous cortisol synthesis/concentrations in absence of DEX</li> <li>healthy male volunteers <ul> <li>(18-60 years)</li> <li>no clinically significant sensitivity to hydrocortisone</li> <li>no clinically significant sensitivity to dexamethasone (DEX)  </li> <li>no infection</li> </ul> </li> <li>performed at Simbec Research Ltd (Merthyr Tydfil, UK)</li> </ul> </li> <li>Formulation<ul> <li>Infacort\u00ae (Diurnal Ltd)</li> <li>HC tablet (Auden Mackenzie Ltd, Ruislip, UK)</li> <li>hydrocortisone succinate (iv)</li> </ul> </li> <li>Administration of HC (08:00 and 13:00)<ul> <li>after which received standardised meals</li> </ul> </li> <li>five study periods<ul> <li>n=14<ul> <li>no signs of insufficient suppression of the HPA axis</li> <li>median values with range<ul> <li>\\(age\\) 28.5 (22.0-60.0) years</li> <li>$body weight $ 82.9 (63.6-102.7) kg</li> <li>\\(height\\) 1.83 (1.68-1.96) m</li> </ul> </li> </ul> </li> <li>1 period without + 4 with DEX </li> <li>single morning oral (po) or iv doses<ul> <li>20  mg </li> </ul> </li> <li>DEX<ul> <li>1 mg </li> <li>in each study period</li> <li>to suppress the endogenous cortisol synthesis</li> </ul> </li> <li>washout period <ul> <li>at least 1 week between last 4 periods</li> </ul> </li> <li>Measurements<ul> <li>Total plasma cortisol concentrations (\\(C_{tot}\\))<ul> <li>every 1.00 h between [0 h, 24 h] in absence of DEX (15:00-15:00)</li> <li>every 0.25 h between [0 h, 3 h] </li> <li>every 1.00 h between [4 h, 6 h]</li> <li>every 2.00 h between [6 h, 12 h]</li> <li>LC-MS/MS<ul> <li>Applied Biosystems MDS Sciex API 365 triple quadrupole atmospheric pressure ionisation mass spectrometer</li> <li>LLOQ of 1.38 nmol/L</li> <li>intra-assay variability 9.6% between [4.14 and 553] nmol/L</li> <li>inter-assay variability 3.7% between [4.14 and 553] nmol/L</li> <li>Accuracy &lt;5% between [0.5, 300] nmol/L</li> </ul> </li> </ul> </li> <li>CBG [2003_Lewis]<ul> <li>ELISA (Biovendor, Czech republic, Brno)<ul> <li>LLOQ of 3.13 ng/mL</li> <li>intra-assay variability &lt; 3.0%</li> <li>inter-assay variability &lt; 8.0%</li> </ul> </li> </ul> </li> <li>unbound cortisol concentrations (\\(C_u\\))<ul> <li>22:00 in absence of DEX</li> <li>07:00 in absence of DEX</li> <li>09:00 in absence of DEX</li> <li>pre dose</li> <li>2.0 h post dose</li> <li>LC/MS-MS<ul> <li>LLOQ of 0.80 nmol/L</li> <li>intra-assay variability &lt;8.0%</li> <li>inter-assay variability &lt;9.5%</li> <li>Accuracy &lt;10.4% for concentrations between [2.7, 72.0] nmol/L [2012_Jones]</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> </ul> <p>Summey of study design of the clinical trial. Figure was adopted from 2018_Melin.</p>"},{"location":"Literature/clinical_trials/#reported-by-charite","title":"Reported by Charite","text":"<ul> <li>[2016_Debono]<ul> <li>EudraCT number: 2014-002265-30 </li> <li>Phase 3 Trial</li> <li>Institute of Experimental Paediatric Endocrinology at Charite-Universit\u00e4tsmedizin Berlin</li> </ul> </li> <li>Population Summary</li> </ul> Cohort Age Range Sample Size Description Cohort 3 birth-28 days n=6 neonates Cohort 2 28 days-2 years n=6 infants Cohort 1 2-6 years n=12 young children <ul> <li>Dose: 1-4 mg<ul> <li>fasted 2h before and 1h (or 30 min for &lt;1 y.o.) after dose </li> </ul> </li> <li>Formulation: opened Infacort\u00ae capsule<ul> <li>granules</li> <li>with a spoon onto the tongue of the child </li> <li>washed down with fluid (milk, juice, water).</li> </ul> </li> <li>Measurements from intravenous cannula<ul> <li>Total plasma cortisol concentrations (\\(C_{tot}\\))<ul> <li>performed at Simbec Research Ltd (Merthyr Tydfil, UK)</li> </ul> </li> <li>CBG<ul> <li>performed at Simbec Research Ltd (Merthyr Tydfil, UK)</li> </ul> </li> <li>albumin</li> </ul> </li> </ul> <p>Study design of the clinical trial. Figure was adopted from PhD thesis of Johanna Melin.</p>"},{"location":"Literature/clinical_trials/#studies-by-charmandari","title":"Studies by Charmandari","text":"<ul> <li>[2001b_Charmandari]</li> <li>[2001c_Charmandari]</li> <li>n=42</li> <li>classical 21-hydroxylase deficiency</li> <li>age: 7-17 years</li> <li>adequate HPA axis suppression<ul> <li>ACTH concentrations at 08:00 &lt;71 pg/mL </li> <li>17-OHP concentrations &lt;20 nmol/L</li> </ul> </li> <li>Exclusion criteria: <ul> <li>inadequate HPA axis suppression<ul> <li>ACTH concentrations at 08:00 &lt;71 pg/mL </li> <li>17-OHP concentrations &lt;20 nmol/L</li> </ul> </li> <li>Patients with signs of precocious puberty</li> <li>other signs of endocrine disorder</li> <li>insufficient dosing history</li> </ul> </li> <li>Standard treatment of fludrocortisone</li> <li>Morning dose<ul> <li>median 123.8 \u03bcg/\\(m^2\\)</li> <li>range 54.0-160.0</li> </ul> </li> <li>po administration<ul> <li>Hydrocortone, Merck Sharp &amp; Dohme Ltd</li> <li>n=17<ul> <li>08:00</li> <li>15:00  </li> <li>22:00</li> </ul> </li> <li>n=13<ul> <li>09:00  </li> <li>21:00</li> </ul> </li> </ul> </li> <li>single iv bolus administration<ul> <li>Solu-Cortef, Pharmacia &amp; Upjohn</li> <li>n=16</li> <li>15 mg/\\(m^2\\)</li> </ul> </li> <li>Measurements <ul> <li>Total plasma cortisol concentrations (\\(C_{tot}\\)) <ul> <li>[2001b_Charmandari]</li> <li>{iv} every 10 min up to 6 h post dose</li> <li>{po} every 20 min up to 24 h</li> <li>solid phase radioimmune assay<ul> <li>Coat-A-Count, DPC, Los Angeles, CA, USA.</li> <li>LLOQ of 21-28 nmol/L</li> <li>inter-assay variability <ul> <li>6.3% for 138 nmol</li> <li>4.5% for 276 nmol</li> </ul> </li> </ul> </li> </ul> </li> <li>17-OHP <ul> <li>[2001c_Charmandari]</li> <li>{po} every 20 min up to 24 h</li> <li>solid phase radioimmune assay<ul> <li>Coat-A-Count, DPC, Los Angeles, CA, USA</li> <li>LLOQ of 0.3 nmol/L</li> <li>inter-assay variability <ul> <li>11% for 1.06 nmol</li> <li>8.5% for 18.5 nmol</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> </ul>"},{"location":"Literature/hydrocortisone/","title":"Hydrocortisone","text":""},{"location":"Literature/hydrocortisone/#introduction","title":"Introduction","text":"<ul> <li>synthetic cortisol<ul> <li>cannot be bioanalytically separated from endogenous cortisol [2018_Melin]</li> </ul> </li> <li>the relatively short half-life of 1.5 h</li> <li>lack of licensed formulation for this population (for &lt;6yo)</li> <li>Dose<ul> <li>still growing children: 8 mg/m\\(^2\\)/day divided in 3-4 doses [2016_Bornstein]</li> <li>more specific:  10-15 mg/m\\(^2\\)/day divided into 3 doses [2010_Speiser]</li> <li>recommended daily dose to adult patients with adrenal insufficiency [2016_Bornstein]<ul> <li>at 06:00 10 mg</li> <li>at 14:00 5 mg</li> <li>at 22:00 5 mg </li> </ul> </li> </ul> </li> <li>modified release formulations [2016_Porter]<ul> <li>Plenadren </li> <li>Chronocort</li> </ul> </li> <li>administration <ul> <li>subcutaneously via insulin -&gt; circadian cortisol profile and improved 17-OHP concentrations [2014_Hindmarsh]</li> </ul> </li> <li>BCS (biopharmaceutical classification system) class II [1995_Amidon]<ul> <li>low dissolution rate and high intestinal permeability [2008_Lennern\u00e4s]</li> </ul> </li> </ul>"},{"location":"Literature/hydrocortisone/#pharmacokinetics","title":"Pharmacokinetics","text":""},{"location":"Literature/hydrocortisone/#absorption","title":"Absorption","text":"<ul> <li>Parameters<ul> <li>passive diffusion and is a poor substrate for the efflux protein P-glycoprotein [2008_Lennern\u00e4s]</li> <li>\\(T_{max}\\)<ul> <li>tablet 1-1.7 h <ul> <li>note: 1.7 h in high dose 50 mg [TBA]</li> </ul> </li> <li>solution 0.7-1 h</li> <li>pediatric adrenal insufficiency 0.33-3 h</li> </ul> </li> <li>\\(t_{1/2,abs}\\) [2004_Mah]<ul> <li>fasting: 15 min</li> <li>fed: 43 min </li> </ul> </li> <li>\\(C_{max}\\)<ul> <li>75th percentile of observed data [1997_Knutsson]</li> </ul> </li> <li>F <ul> <li>100% when dose of &lt;20 mg</li> <li>54% when dose of 50 mg in patients with adrenal insufficiency [1984_Heazelwood]</li> </ul> </li> </ul> </li> </ul>"},{"location":"Literature/hydrocortisone/#distribution","title":"Distribution","text":"<ul> <li>Parameters<ul> <li>\\(V_{c}\\)<ul> <li>7 to 23.9 L iv</li> <li>28.4 L when dose of 50 mg in patients with adrenal insufficiency [1984_Heazelwood]</li> </ul> </li> <li>\\(V_{c}/F\\) or relative volume of distribution<ul> <li>38.7-52.3 L patients with adrenal insufficiency</li> <li>17.5 \u00b1 10.5 L pediatric patients [2015_Sarafoglou]</li> <li>27.1 \u00b1 8.4 L prepubertal </li> <li>49.5 \u00b1 12.2 L pubertal</li> <li>40.8 \u00b1 16.0 L prepubertal<ul> <li>[2001a_Charmandari]</li> </ul> </li> </ul> </li> <li>\\(V_{ss}\\)<ul> <li>increasing with increasing doses [1981_Toothaker]</li> <li>5 mg: 20.7 \u00b1 7.3 L</li> <li>40 mg: 37.5 \u00b1 5.8 L</li> </ul> </li> </ul> </li> </ul>"},{"location":"Literature/hydrocortisone/#metabolism","title":"Metabolism","text":"<ul> <li>[2006_Hoshiro]<ul> <li>11\u03b2-hydroxysteroid dehydrogenase<ul> <li>bidirectional </li> <li>type 1 (11\u03b2-HSD1) to cortisol liver and adipose<ul> <li>undetectable \\(&lt;3\\) months</li> <li>stabilized approx. at 12 months</li> </ul> </li> <li>type 2 (11-\u03b2HSD2) to cortisone in kidney<ul> <li>increased from 0-52 weeks,</li> </ul> </li> </ul> </li> <li>5\u03b1-reductase(cortisol) and 5\u03b2-reductase (cortisone)<ul> <li>unidirectional<ul> <li>low in newborns </li> <li>highest activity &gt;3 months</li> <li>declined &lt;52 weeks </li> <li>similar 3.5-17.5 years </li> </ul> </li> </ul> </li> <li>3\u03b1-hydroxysteroid<ul> <li>unidirectional</li> </ul> </li> <li>6\u03b2-hydroxylase (CYP3A4)<ul> <li>unidirectional</li> <li>approx. 1%</li> </ul> </li> </ul> </li> </ul> <p>Metabolic pathway of cortisol. Figures were adapted from PhD thesis of Johanna Melin. Created using diagrams.net</p>"},{"location":"Literature/hydrocortisone/#elimination","title":"Elimination","text":"<ul> <li>At least 90% of cortisol and cortisone metabolites are normally excreted as sulfate or glucuronide conjugates. Conjugation of cortisol and cortisone can occur at the 21 position, and 3\u03b1-reduced steroids can also be conjugated at the 3\u03b1 position</li> <li>Parameters<ul> <li>\\(CL\\)<ul> <li>dose-dependent CL</li> <li>lower in neonates (due to maturation of metabolic enzymes)</li> <li>12.5 to 20.2 L/h (iv 5-50 mg)</li> <li>12.5 L/h (iv 5 mg)</li> <li>17.6 L/h (iv 40 mg)</li> <li>note: Saturation of CBG leads to \\(CL_u\\) increasing disproportionally with respect to \\(CL_{tot}\\).</li> <li>CL (\\(CL_u\\))  remains constant, since it is independent of \\(f_u\\).</li> </ul> </li> <li>\\(CL/F\\)<ul> <li>19.1 L/h (oral 10-20 mg: F\u22481)</li> <li>27.3 L/h (50 mg)</li> <li>12.4-25.6 L/h (patients with adrenal insufficiency)</li> <li>note: highest value in pubertal patients</li> </ul> </li> <li>\\(AUC\\)<ul> <li>nonlinear processes (e.g. saturable plasma protein binding or saturable absorption)</li> </ul> </li> </ul> </li> </ul>"},{"location":"Literature/hydrocortisone/#pharmacodynamics","title":"Pharmacodynamics","text":"<ul> <li>Effect<ul> <li>endogenous cortisol synthesis</li> <li>T cell dynamics [2003_Mager]</li> </ul> </li> <li>correlation with 17-OHP concentration <ul> <li>1 h post dose</li> <li>delayed inhibitory effect with r=-0.302 [2001a_Charmandari]</li> </ul> </li> <li>no correlation between AUC for cortisol and 17-OHP [2015_Sarafoglou]</li> </ul>"},{"location":"Literature/hydrocortisone/#formulations-and-administration","title":"Formulations and Administration","text":"<ul> <li>Lowest available dose for a oral tablet<ul> <li>5  mg in USA</li> <li>10 mg in Europe or Canada</li> </ul> </li> </ul>"},{"location":"Literature/hydrocortisone/#infacort","title":"Infacort \u00ae","text":"<ul> <li>Diurnal Ltd</li> <li>immediate-release hydrocortisone</li> <li>Brand name: Alkindi (with four doses: 0.5 mg, 1 mg, 2 mg and 5 mg)</li> <li>Approval for children with adrenal insufficiency from regulatory agencies [2018_Neumann]<ul> <li>EMA - 2018</li> <li>FDA - 2020</li> </ul> </li> <li>oral (po)</li> <li>hydrocortisone granules with taste masking<ul> <li>dry granules or mixed with a small amount of soft food</li> </ul> </li> <li>analysis in adults with a NCA by [2015_Whitaker]<ul> <li>does not account for known nonlinearities of cortisol</li> </ul> </li> <li>good disease control with normal growth and no increased risk of adrenal crises [2021_Neumann]</li> </ul>"},{"location":"Literature/hydrocortisone/#licensed-hydrocortisone-tablet","title":"Licensed Hydrocortisone tablet","text":"<ul> <li>Auden Mackenzie Ltd</li> <li>oral (po)</li> </ul>"},{"location":"Literature/hydrocortisone/#hydrocortisone-succinate","title":"Hydrocortisone Succinate","text":"<ul> <li>intravenous (iv) bolus </li> <li>HC administration</li> </ul>"},{"location":"Literature/hydrocortisone/#hydrocortisone-cypionate-suspension","title":"Hydrocortisone cypionate suspension","text":"<ul> <li>Pharmacia &amp; UpJohn</li> <li>voluntarily recalled in July 2000 [2001_Merke]</li> <li>possible inaccuracies in preparations can lead to unanticipated adverse effects [2018_Barillas]</li> </ul>"},{"location":"Literature/prelim/","title":"Preliminary research","text":""},{"location":"Literature/prelim/#jme_1","title":"JMe_1","text":"<ul> <li>Published information from 2018_Melin</li> </ul>"},{"location":"Literature/prelim/#population-pharmacokinetic-analysis","title":"Population Pharmacokinetic Analysis","text":"<ul> <li>NONMEM 7.3 and Perl speaks NONMEM (PsN 4.4.0)</li> <li>LLOQ data were disregarded as it was 4% of \\(C_u\\) data</li> </ul>"},{"location":"Literature/prelim/#binding-model-and-cbg-model","title":"Binding model and CBG model","text":"<ul> <li>first-order conditional estimation with interaction</li> <li>using log transformed \\(C_{tot}\\) data<ul> <li>which had corrresponding \\(C_u\\) data</li> </ul> </li> <li> <p>Binding model: $$C_b = \\frac{B_{max} \\cdot C_u}{K_d + C_u} + NS \\cdot C_u $$</p> <p>\\(C_b\\) - bound cortisol concentration \\(B_{max}\\) - maximal binding capacity \\(K_d\\) - equilibrium dissociation constant \\(NS\\) - linear nonspecific binding </p> </li> <li> <p>CBG model:</p> <ul> <li>constant CBG after DEX administration</li> <li>CBG was used as a covariate for \\(B_{max}\\)</li> </ul> </li> </ul>"},{"location":"Literature/prelim/#semi-mechanistic-pharmacokinetic-model","title":"Semi-mechanistic pharmacokinetic model","text":"<ul> <li>Stochastic Approximation Expectation Maximisation method with interaction followed by Monte-Carlo Importance Sampling Expectation Maximisation method</li> <li>using log transformed \\(C_{tot}\\) data</li> <li>\\(C_{tot}\\) before and after treatment were similar<ul> <li>constant cortisol baseline (Baselinecort) was estimated</li> </ul> </li> <li> <p>Equation for \\(C_{tot}\\) \\(\\(C_{tot} = \\frac{A_c}{V_c} + baseline_{cort}\\)\\)</p> <p>\\(C_{tot}\\) - predicted total cortisol concentration in the central compartment \\(A_c\\) - total amount in central compartment \\(V_c\\) - central volume of distribution \\(baseline_{cort}\\) - individual cortisol baseline</p> </li> <li> <p>Time course of \\(A_{depot}\\) \\(\\(\\frac{dA_{depot}}{dt} = \\frac{-V_{max} \\cdot A_{depot}}{K_m + A_{depot}}\\)\\)</p> <p>\\(A_{u}\\) unbound amount in the central compartment \\(V_c\\) peripheral compartment \\(Q\\) intercompartmental clearance \\(CL\\) elimination constant </p> </li> <li>binding model was included<ul> <li>with fixed parameters</li> </ul> </li> <li>IIV<ul> <li>exponential model, assuming a log-normal distribution of structural pharmacokinetic parameters</li> <li>fixed CV of 15% for fixed parameters</li> </ul> </li> <li>RUV<ul> <li>generally: additive error on the log scale</li> <li>CBG model: proportional error model on linear scale</li> </ul> </li> </ul>"},{"location":"Literature/prelim/#model-evaluation","title":"Model Evaluation","text":"<ul> <li>goodness-of-fit plots</li> <li>parameter plausibility  </li> <li>parameter precision<ul> <li>parameteric bootstraps in PsN (n = 1000)</li> </ul> </li> <li>Predictive performance<ul> <li>visual predictive checks (VPCs)</li> </ul> </li> <li>objective function value (OFV).<ul> <li>nested models: likelihood ratio test </li> <li>unnested models: AIC</li> </ul> </li> <li>binding model evaluation<ul> <li>using VPC with plasma protein binding data from [1999_Lentjes]</li> </ul> </li> </ul>"},{"location":"Literature/prelim/#simulations","title":"Simulations","text":"<ul> <li>simulated in R 3.3.0</li> <li>different concentrations of cortisol <ul> <li>using the developed binding model and </li> <li>the typical CBG baseline</li> <li>\\(C_{tot}\\) range was explored: 23.7-492 nmol/L</li> </ul> </li> <li>dose\u2013exposure relationship <ul> <li>using semi-mechanistic pharmacokinetic model</li> <li>different BW (5\u2013100 kg) and the typical CBG concentration</li> <li>\\(C_{max}\\) and AUC<ul> <li>2.2\u201318.5 years</li> <li>was analysed and compared to literature data [1997_Knutsson]</li> </ul> </li> <li>\\(C_{max}\\)<ul> <li>25th\u201375th percentiles of the Cmax for the morning peak in children</li> </ul> </li> <li>AUC comparison range <ul> <li>95% confidence interval</li> <li>one-third of the 24 h AUC for children, </li> <li>assuming a recommended 3 times/day with equal doses</li> </ul> </li> </ul> </li> </ul>"},{"location":"Literature/prelim/#vst","title":"VSt","text":""},{"location":"Literature/prelim/#dbi","title":"DBi","text":"<p>*</p>"},{"location":"Literature/system_components/","title":"System Components","text":""},{"location":"Literature/system_components/#cortisol","title":"Cortisol","text":"<ul> <li>major glucocorticoid</li> <li>Chemical properties<ul> <li>\\(C_{21}H_{30}O_5\\)</li> <li>Average mass: 362.460 Da or g/mol [ChemsSpider]</li> <li>IUPAC name: 11\u03b2,17\u03b1,21-Trihydroxypregn-4-ene-3,20-dione</li> <li>Molecule Type: Small molecule</li> </ul> </li> </ul> <p>Chemical Structure of Cortisol. Figure from ChEMBL.</p> <p></p> <p>Chemical structure of Cortisol. Created using py3Dmol tool.</p> <p></p> <p>Interactive chemical structure of Cortisol. Created using 3Dmol.js tool.</p> <ul> <li>a negative feedback on CRH and ACTH release, thereby inhibiting the HPA axis [2002_Tsigos]</li> <li>saturable plasma protein binding of cortisol occurring at high cortisol concentrations [1981_Toothaker]</li> <li>maturation factors<ul> <li>amount of body water<ul> <li>80-85% in young infants</li> <li>55-60% in adults</li> </ul> </li> <li>fat content<ul> <li>10-15% at birth</li> </ul> </li> <li>maturation of plasma proteins</li> <li>\u2193\\([CBG]\\) in neonates = \u2191 \\(CL_u\\) [1975_Hadjian]</li> </ul> </li> </ul>"},{"location":"Literature/system_components/#cbg","title":"CBG","text":"<ul> <li>Corticosteroid-Binding Globulin</li> <li> <p>low conc. relative to albumin</p> <ul> <li>albumin: 35,000-50,000 mg/L [1992_Peters]</li> <li>CBG: 14.9-67.1 mg/L [2003_Lewis]<ul> <li>elevated: <ul> <li>pregnant women (2-3 fold) [2011_Henley]</li> <li>synthetic oral oestrogens [1967_Musa]</li> <li>Mitotane, an adrenolytic agent for adrenocortical carcinoma [1991_Vanseters]</li> <li>some patients with chronic active hepatitis</li> </ul> </li> <li>reduced: <ul> <li>neonates (note: infants reach adult values) [1975_Hadjian]</li> <li>patients with Cushing's syndrome (33.2 \u00b1 5.6 mg/L) [1986_Coolens]</li> </ul> </li> </ul> </li> </ul> </li> <li> <p>Saturation of CBG</p> <ul> <li>at total cortisol concentrations (\\(C_{tot}\\)) above 200 ng/mL or 550 nmol/L [1981_Toothaker]</li> <li>unbound cortisol concentration (\\(C_{u}\\)) increases disproportionally with respect to \\(C_{tot}\\)</li> </ul> </li> <li>lower in neonates, whereas infants had reached adult values</li> <li>3D structure [2007_Klieber]</li> </ul> <p></p> <p>Chemical structure of CBG. Created using py3Dmol tool.</p> <p></p> <p></p> <p>Interactive chemical structure of CBG. Created using 3Dmol.js tool.</p>"},{"location":"Literature/system_components/#17-ohp","title":"17-OHP","text":"<ul> <li>17-hydroxyprogesterone or 17-OH-Progesterone</li> <li>used as biomarker of CAH</li> <li>seems to have a circadian variation (&gt;12 months) [2003_Groschl]</li> <li>conc. range of 12-36 nmol/L -&gt; target for therapy [2005_Merke]<ul> <li>note: when measured in the early morning before medication</li> </ul> </li> </ul> <p>Chemical structure of 17-OHP. Created using py3Dmol tool.</p> <p></p> <p>Interactive chemical structure of 17-OHP. Created using 3Dmol.js tool.</p>"},{"location":"Literature/system_components/#acth","title":"ACTH","text":"<ul> <li>AdrenoCorticoTrophic Hormone</li> <li>[link]</li> <li>Increased production in CAH <ul> <li>due to <ul> <li>feedback loop from decreased cortisol production</li> <li>aldosterone insufficiency -&gt; volume depletion -&gt; vasopressin synthesis [2000_Arvat]</li> </ul> </li> <li>leads to [2020_Merke]<ul> <li>adrenocortical hyperplasia as well as the </li> <li>synthesis of adrenal androgens and androgen precursors, </li> <li>synthesis of 17-OHP and androstenedione</li> </ul> </li> </ul> </li> </ul>"},{"location":"Literature/system_components/#hpa-axis","title":"HPA-axis","text":"<ul> <li>Hypothalamic-Pituitary-Axis</li> <li>follow a circadian rhythm</li> <li>Cortisol is inhibits the HPA axis<ul> <li>major glucocorticoid and </li> <li>negative feedback on CRH and ACTH release</li> </ul> </li> <li>Classic CAH<ul> <li>absence of negative feedback</li> <li>increased production of corticotropin-releasing factor (CRF) in hypothalamus</li> <li>increased production of adrenocorticotrophic hormone (ACTH) in pituitary gland</li> <li>main reason for overproduction of androgens</li> </ul> </li> </ul>"},{"location":"Literature/system_components/#steroid-synthesis","title":"Steroid synthesis","text":"<ul> <li>Steroid synthesis of mineralocorticoids, glucocorticoids and androgens</li> <li>healthy and CAH</li> </ul> <p>Steroid synthesis pathway. Figures were adopted from PhD thesis of Johanna Melin.</p>"},{"location":"NLMEM/","title":"NLMEM","text":"<ul> <li>NonLinear Mixed-Effects Models</li> <li>Aim<ul> <li>to generate parameter estimates that describe the observed data most appropriately</li> <li>using maximum likelihood estimation</li> <li>iteratively selects parameters maximising the probability of observing the data</li> </ul> </li> <li>Approach<ul> <li>Analysing the population and individual level simultaneously <p>mixed-effects modelling = fixed-effects + random-effects</p> </li> </ul> </li> </ul>"},{"location":"NLMEM/baseline_models/","title":"Baseline models","text":"<ul> <li>to consider the baseline values observed before and after treatment <ul> <li>e.g. endogenous synthesis of cortisol</li> <li>e.g. endogenous biomarker (17-OHP)</li> </ul> </li> <li>4 types of methods [2008_Dansirikul]</li> </ul>"},{"location":"NLMEM/baseline_models/#b1","title":"B1","text":"<ul> <li>individual baseline was derived considering IIV (\\(\u03b7_i\\)) and the population baseline</li> <li>assuming a log-normal distribution of the baseline</li> <li>does not require pre-dose measurements</li> <li>seen as the gold standard</li> <li>independent of the data</li> <li>superior to the B2 method</li> </ul> \\[baseline_\ud835\udc56 = baseline \\cdot \ud835\udc52^{\ud835\udf02_\ud835\udc56}\\]"},{"location":"NLMEM/baseline_models/#b2","title":"B2","text":"<ul> <li>estimated \\(baseline_i\\) is informed by<ul> <li>the individually observed initial concentration (\\(baseline_{obs,i}\\))</li> <li>the interindividual variability corresponding to the residual variability (\\(\u03b7_i,RV\\))</li> </ul> </li> </ul> \\[\ud835\udc4f\ud835\udc4e\ud835\udc60\ud835\udc52\ud835\udc59\ud835\udc56\ud835\udc5b\ud835\udc52_\ud835\udc56=\ud835\udc4f\ud835\udc4e\ud835\udc60\ud835\udc52\ud835\udc59\ud835\udc56\ud835\udc5b\ud835\udc52_{\ud835\udc5c\ud835\udc4f\ud835\udc60,\ud835\udc56} \\cdot \ud835\udc52^{\ud835\udf02_\ud835\udc56,\ud835\udc45\ud835\udc49}\\]"},{"location":"NLMEM/baseline_models/#b3","title":"B3","text":"<ul> <li>[TBA]</li> </ul>"},{"location":"NLMEM/baseline_models/#b4","title":"B4","text":"<ul> <li>[TBA]</li> </ul>"},{"location":"NLMEM/bllq/","title":"Handling BLLQ data","text":"<ul> <li>Below Lower Limit of Quantification</li> <li>not always possible to improve the LLOQ of the bioanalytical assays [2008_Ahn]</li> <li>ignoring data below LLOQ [2001_Beal]<ul> <li>biased and slightly overpredicted near or below LLOQ  </li> </ul> </li> <li>BLQ observations should be considered if the fraction BLQ is larger than 10% [2007_Byon]</li> <li>censoring BLQ in data with a low fraction BLQ (10%) [2011_Xu]<ul> <li>1-CMT model: minor impact</li> <li>2-CMT model: more impact</li> </ul> </li> <li>4 types of methods<ul> <li>the improvement depends on model complexity and fraction of observations below LLOQ [2001_Beal]</li> </ul> </li> </ul>"},{"location":"NLMEM/bllq/#m1","title":"M1","text":"<ul> <li>Censoring observations below LLOQ</li> </ul>"},{"location":"NLMEM/bllq/#m2","title":"M2","text":"<ul> <li>[TBA]</li> </ul>"},{"location":"NLMEM/bllq/#m3","title":"M3","text":"<ul> <li>the likelihood for the observations below LLOQ is assessed</li> <li>may not be possible for more complex models<ul> <li>generally provides more accurate parameter estimates over M1 [2008_Ahn] [2009_Bergstrand]</li> </ul> </li> </ul>"},{"location":"NLMEM/bllq/#m4","title":"M4","text":"<ul> <li>[TBA]</li> </ul>"},{"location":"NLMEM/evaluation/","title":"Model Selection and Evaluation","text":""},{"location":"NLMEM/evaluation/#numerical-and-statistical-evaluation","title":"Numerical and statistical evaluation","text":""},{"location":"NLMEM/evaluation/#ofv","title":"OFV","text":"<ul> <li>Objective Function Value</li> <li>minimising the -2LL</li> <li>lower OFV indicates a better fit</li> <li>likelihood ratio test [2014_Owen]<ul> <li>for nested models (complex models which can be collapsed to the simpler one)</li> <li>not useful to compare distinct models</li> <li>\\(\u03c7^2\\) distribution</li> <li>null hypothesis: no difference between models</li> <li>hypothesis: difference between models</li> <li>significance level (\u03b1) of 0.01: <ul> <li>OFV of 6.63 (degrees of freedom=1 or an increase of 1 parameter)</li> <li>OFV of 9.21 (degrees of freedom=2 or an increase of 2 parameters)</li> <li>etc.</li> </ul> </li> <li></li> </ul> </li> </ul> \\[OFV_{ELS} = \\sum_{i=1}^{n} \\left[ \\frac{(y_i - \\hat{y}_i)^2}{\\text{var}(y_i)} + \\ln(\\text{var}(y_i)) \\right] \\] <p>\\(n\\) is the number of observations;  \\(y_i\\) is the observed value for the \\(i^{th}\\) observation;  \\(\\hat{y}_i\\) is the predicted/expected value for the \\(i^{th}\\) observation;  \\(\\text{var}(y_i)\\) is the variance of the \\(i^{th}\\) observation.</p> Degrees of Freedom \u03b1=0.05 \u03b1=0.01 \u03b1=0.001 1 3.841 6.635 10.828 2 5.991 9.210 13.816 3 7.815 11.345 16.266 4 9.488 13.277 18.467 5 11.070 15.086 20.515 6 12.592 16.812 22.458 7 14.067 18.475 24.322 8 15.507 20.090 26.125 9 16.919 21.666 27.877 10 18.307 23.209 29.588"},{"location":"NLMEM/evaluation/#aic","title":"AIC","text":"<ul> <li>Akaike Information Criterion</li> <li>penalties are applied as a function of increased number of parameters</li> <li>[1974_Akaike] [2006_Bonate] <ul> <li>not nested </li> <li>lower AIC indicates the better fit </li> </ul> </li> </ul> \\[AIC=OFV+2 \\cdot p\\]"},{"location":"NLMEM/evaluation/#bic","title":"BIC","text":"<ul> <li>Bayesian Information Criterion</li> <li>penalties are applied as a function of increased number of parameters [2014_Delattre]</li> <li>1978_Schwarz<ul> <li>not nested </li> <li>lower BIC indicates the better fit </li> </ul> </li> </ul> \\[ \\text{BIC}_{\\text{mixed}} = \\text{OFV} + p_{\\text{random}} \\cdot \\ln(n_{\\text{id}}) + p_{\\text{fixed}} \\cdot \\ln(n_{\\text{obs}}) \\] <p>\\(\\text{OFV} = -2 \\times \\ln(L)\\) - Objective Function Value, where \\(L\\) is the likelihood of the model;  \\(p_{\\text{random}}\\) - number of random effects parameters;  \\(p_{\\text{fixed}}\\) - number of fixed effects parameters;  \\(n_{\\text{id}}\\) - number of unique individuals (clusters);  \\(n_{\\text{obs}}\\) - number of observations.</p>"},{"location":"NLMEM/evaluation/#graphical-evaluation","title":"Graphical evaluation","text":"<ul> <li>models can be evaluated by visual examination of data plots [1992_Mandema]</li> </ul>"},{"location":"NLMEM/evaluation/#gof","title":"GOF","text":"<ul> <li>Standard Goodness of Fit</li> <li>comparison of the predicted versus the observed concentrations</li> <li>observations should be scattered evenly around the line of identity</li> <li>CWRES (conditional weighted residuals)<ul> <li>adjusted based on the FOCE approximation [2007_Hooker]</li> <li>should be [2013_Mould]<ul> <li>close to zero (\u00b1 2 SD)</li> <li>randomly scattered around zero</li> </ul> </li> </ul> </li> <li>CWRES vs. population predictions<ul> <li>identification of concentration-dependencies</li> <li>to assess appropriateness of the RUV model</li> </ul> </li> <li>CWRES vs. time<ul> <li>identification of time-dependencies</li> <li>specification appears in the absorption or the elimination phase.</li> </ul> </li> </ul>"},{"location":"NLMEM/evaluation/#vpc","title":"VPC","text":"<ul> <li>Visual Predictive Check</li> <li>model diagnostics [2008_Karlsson]<ul> <li>constructing simulated data using the developed model and </li> <li>comparing it with the existing dataset </li> </ul> </li> <li>simulation-based graphical evaluation</li> <li>to evaluate predictive performance of a model</li> <li>the ability of a model to reproduce the observed data</li> <li>procedure [2011_Bergstrand]<ul> <li>The percentiles of interest (commonly 5th,50th and 95th)</li> <li>the confidence interval of respective percentiles for the simulated concentrations</li> <li>compared graphically with the same percentiles of the observed concentrations</li> <li>derived for selected time ranges (bins) </li> <li>not at every time to ease the comparison</li> </ul> </li> <li>percentiles of the simulated and observed data are compared graphically [2008_Holford]</li> <li>Categorical VPC is a useful tool to evaluate performance for categorical data [2009_Bergstrand]</li> </ul>"},{"location":"NLMEM/evaluation/#evaluation-of-uncertainty-in-parameter-estimates","title":"Evaluation of uncertainty in parameter estimates","text":"<ul> <li>variance-covariance matrix <ul> <li>generated in NONMEM</li> <li>standard errors of the parameter estimates <ul> <li>the square root of the diagonal elements in variance-covariance matrix</li> </ul> </li> </ul> </li> <li>%RSE relative standard error<ul> <li>to evaluate parameter precision for fixed-effects</li> <li>&lt;30% are acceptable [2014_Owen]</li> </ul> </li> </ul> \\[RSE(\\theta) = 100 \\cdot \\frac{SE(\\theta)}{\\theta}\\] <p>\\(\u03b8\\) the final population parameter;  \\(SE(\u03b8)\\) standard error of the population parameter.</p> <ul> <li>%RSE for random-effects parameters<ul> <li>40-50% is acceptable [2014_Owen]</li> </ul> </li> </ul> \\[RSE(\\omega^2) = 100 \\cdot \\frac{SE(\\omega^2)}{2 \\cdot \\omega^2}\\] <p>\\(\\omega^2\\) final variance;  \\(SE(\\omega^2)\\) standard error of final variance.</p> <ul> <li> <p>Bootstrap method [2005_Lindbom]</p> <ul> <li>generated from the original dataset</li> <li>sampling individuals with replacement</li> <li>new parameter estimates are generated </li> <li>derived confidence interval (e.g. 95% CI)</li> <li>\\(&gt;200\\) datasets may be needed to generate the standard errors</li> <li>can be generated using PsN software</li> </ul> </li> <li> <p>Log-Likelihood profiling</p> <ul> <li>to assess if the OFV from the final model refers to the global minimum</li> <li>surface of the likelihood between the full and reduced model<ul> <li>re-estimation by fixing the respective parameter to a slightly different estimate (e.g. \u00b15% or \u00b120%) </li> <li>until the selected significant difference in likelihood (e.g. \u0394OFV: 3.84, df=1, \u03b1=0.05) is achieved</li> <li>the lower and upper boarder of the 95% confidence interval for the parameter has been reached [2014_Owen] [2018_PsN_LLP]</li> </ul> </li> </ul> </li> </ul>"},{"location":"NLMEM/evaluation/#influential-individuals","title":"Influential Individuals","text":"<ul> <li>may have a large impact on <ul> <li>model selection</li> <li>parameter estimates</li> </ul> </li> <li>Comparison of individual OFV in the NONMEM output</li> <li>Case-deletion diagnostics<ul> <li>new datasets where one individual has been removed</li> <li>influential individual if<ul> <li>a relative change in parameter estimates of \u00b120% [2011_Bonate]</li> </ul> </li> </ul> </li> </ul>"},{"location":"NLMEM/evaluation/#simulations","title":"Simulations","text":"<ul> <li>Deterministic<ul> <li>do not consider the random-effects parameters of the model</li> <li>generating the typical concentration-time profile for a given set of covariates</li> <li>useful to visualise and assess which impact changes in dose will have on e.g. exposure</li> </ul> </li> <li>Stochastic<ul> <li>consider the random-effects parameters</li> <li>used when generating VPCs</li> <li>require appropriate precision of all parameters</li> <li>to guide dose selection </li> <li>to compare different dosing scenarios</li> </ul> </li> </ul>"},{"location":"NLMEM/model_components/","title":"Model components","text":"<ul> <li>Models<ul> <li>represented in the form of mathematical relationships </li> <li>to answer certain questions and aid particular purposes </li> <li>using a combination of models:<ul> <li>structural model;</li> <li>pharmacostatistical model;</li> <li>covariate model.</li> </ul> </li> </ul> </li> </ul>"},{"location":"NLMEM/model_components/#structural-model","title":"Structural model","text":"<ul> <li>mathematical form of algebraic/differential equations <ul> <li>parameters, their relationships, or rate of change [2007_Fisher] [2012_Mould]</li> <li>parameters are considered as \u201ctrue\u201d values for the population with possible variability [2007_Fisher]</li> </ul> </li> <li>describes the central tendency in the data<ul> <li>\"e.g. the central tendency of the cortisol concentration-time profiles after administration of hydrocortisone\"</li> </ul> </li> <li>to develop the simplest model, which still describes the data accurately [2004_Ette]</li> </ul> \\[y_{ij}=f(\ud835\udf19_{i},  x_{ij})\\] <p>\\(i\\) - certain individual; \\(j\\) - certain timepoint; \\(f\\) - a nonlinear function; \\(\ud835\udf19\\) - vector of model parameters (\\(CL\\), \\(V_c\\)); \\(x\\) - study design variables (covariates, dose and sampling times).</p>"},{"location":"NLMEM/model_components/#pharmacostatistical-model","title":"Pharmacostatistical model","text":"<ul> <li>describes the variability, which can be subdivided into IIV and RUV models [1993_Karlsson] [2013_Mould]</li> <li>several hierarchical levels of pharmacostatistical models</li> </ul>"},{"location":"NLMEM/model_components/#iiv","title":"IIV","text":"<ul> <li>InterIndividual Variability</li> <li>difference between individuals</li> <li>allows for the individual parameter estimate to differ from the population estimate</li> <li>\\(\ud835\udf02_i\\)<ul> <li>discrepancy between the population estimate and individual model parameter</li> <li>Empirical bayes estimates, or EBE</li> <li>independent of each other </li> <li>normally or log-normally distributed around 0 [2007_Fisher] [2013_Mould]</li> <li>variance of \\(\u03c9^2\\) </li> <li>the same within an individual unless IOV is applied</li> <li>can be added as:<ul> <li>additive</li> <li>proportional</li> <li>exponential<ul> <li>the most common as parameters are usually log-normally distributed and non-negative values</li> </ul> </li> </ul> </li> </ul> </li> </ul> \\[\ud835\udf19_{i}=g(\ud835\udf03,  z_{i}) + \ud835\udf02_i\\] \\[\ud835\udf19_{i}=g(\ud835\udf03,  z_{i}) \\cdot (1+ \ud835\udf02_i)\\] \\[\ud835\udf19_{i}=g(\ud835\udf03,  z_{i}) \\cdot e^{\ud835\udf02_i}\\] <p>\\(i\\) - certain individual; \\(\ud835\udf19\\) - vector of model parameters (\\(CL\\), \\(V_c\\)); \\(\u03b8\\) - population parameter estimates; \\(z_{i}\\) - covariates.</p>"},{"location":"NLMEM/model_components/#iov","title":"IOV","text":"<ul> <li>InterOccasion Variability</li> <li>variability between different occasions</li> <li>depends on study design (different doses/days/study periods...)</li> <li>does not describe the reason for the variability between occasions</li> <li>should only be used if the model parameters change randomly between occasions</li> <li>\\(k_i\\) [1993_Karlsson]<ul> <li>normally distributed around 0 </li> <li>variance of \\(\u03c0^2\\)</li> </ul> </li> </ul> \\[\ud835\udf19_{i}=g(\ud835\udf03,  z_{i}) \\cdot e^{\ud835\udf02_i+k_i}\\]"},{"location":"NLMEM/model_components/#ruv","title":"RUV","text":"<ul> <li>Residual Unexplained Variability</li> <li>to explain the difference between model-predicted values and observations in the form of distribution variance [2007_Fisher] [2013_Mould]</li> <li>unexplained variability<ul> <li>e.g. resulted by measurement error, model misspecification and errors in dosing</li> </ul> </li> <li>discrepancy between the observed and individually predicted</li> <li>\\(\u03b5_{ij}\\)<ul> <li>normally distributed around 0 </li> <li>variance of \\(\u03c3^2\\)</li> <li>can be added as<ul> <li>additive<ul> <li>If estimating parameters using log-transformed data an additive model is commonly applied, since it approximates an exponential or a proportional RUV model on a linear scale</li> </ul> </li> <li>proportional</li> <li>combined</li> </ul> </li> </ul> </li> </ul> \\[y_{ij}=f(\ud835\udf19_{i},  x_{ij}) + \u03b5_{add,ij}\\] \\[y_{ij}=f(\ud835\udf19_{i},  x_{ij}) \\cdot (1+ \u03b5_{prop,ij})\\] \\[y_{ij}=f(\ud835\udf19_{i},  x_{ij}) \\cdot (1+ \u03b5_{prop,ij}) + {add,ij}\\]"},{"location":"NLMEM/model_components/#covariate-model","title":"Covariate model","text":"<ul> <li>explain variability using observable factors between subjects [2013_Mould]<ul> <li>e.g. age, disease progression, height, weight, or interacting agents/drugs </li> </ul> </li> <li>whether any dose adjustments are needed in specific populations</li> <li>potentially reducing some unexplained IIV [2012_Mould]<ul> <li>body size related covariates</li> <li>creatinine clearance for drugs with renal elimination</li> <li>time-varying covariates [2004_Wahlby]</li> </ul> </li> </ul> \\[\ud835\udf19_{i}=\ud835\udf03 + \ud835\udf03_{cov} \\cdot (z_{i}-z_{median})\\] <p>\\(\u03b8\\) - population parameter; \\(\u03b8_{cov}\\) - covariate effect; \\(z_{i}\\) - individual covariate value; \\(z_{median}\\) - median value of the covariate.</p>"},{"location":"NLMEM/model_components/#final-model","title":"\"Final model\"","text":"<ul> <li>needs to have a scientific basis and descriptive and predictive power to address given clinical questions [2012_Mould]</li> <li>based on components, mechanisms, and assumptions, which should be <ul> <li>credible;</li> <li>reasonable; </li> <li>comparable with existing system components.</li> </ul> </li> </ul>"},{"location":"NLMEM/parameter_estimation/","title":"Parameter Estimation","text":"<ul> <li>parameter values define \u201cgoodness\u201d of the model</li> </ul>"},{"location":"NLMEM/parameter_estimation/#objective-function-value","title":"Objective Function Value","text":"<ul> <li>represents the goodness of fit [2013_Mould]</li> <li>proportional to minus 2 times the log likelihood (-2LL)</li> <li>extended least squares ELS objective function [1980_Sheiner]</li> <li>the preference is given to lower OFV [2013_Mould]<ul> <li>by iterative \u201chill climbing\u201d procedure to find the lowest OFV, or minima, within a given search space. [2008_Cambini]</li> </ul> </li> <li>Initial parameter estimates have an important role [2015_Sale]<ul> <li>estimation can be \u201ctrapped\u201d gradient search in local OFV minima, and \u201cmask\u201d the global minimum </li> </ul> </li> </ul> <p> Figure was adopted from [2015_Sale].</p>"},{"location":"NLMEM/parameter_estimation/#algorithms","title":"Algorithms","text":""},{"location":"NLMEM/parameter_estimation/#gradient-based-algorithms","title":"Gradient-based algorithms","text":"<ul> <li>Taylor series approximations for numerical solution of the likelihood function</li> <li></li> </ul>"},{"location":"NLMEM/parameter_estimation/#foce","title":"FOCE","text":"<ul> <li>First-Order Conditional Estimation algorithm</li> <li>linearised by conditioning on the individual etas [2014_Owen] [2014_Johansson]</li> </ul>"},{"location":"NLMEM/parameter_estimation/#focei","title":"FOCEI","text":"<ul> <li>First-Order Conditional Estimation algorithm with interaction</li> <li>considering the interaction between \u03b5 and \u03b7 [2014_Owen]</li> </ul>"},{"location":"NLMEM/parameter_estimation/#laplace","title":"LAPLACE","text":"<ul> <li>[2014_Johansson]</li> <li>second-order approximation</li> <li>only gradient-based estimation method </li> <li>can be used for categorical data</li> <li>can be used to consider observations below LLOQ</li> <li>more unstable than e.g. FOCE</li> </ul>"},{"location":"NLMEM/parameter_estimation/#saem","title":"SAEM","text":"<ul> <li>Stochastic Approximation Expectation Maximisation</li> <li>[2007_Bauer]</li> <li>step E: stochastic approximation</li> <li>step M: maximises the expected likelihood</li> <li>includes one burn-in and one accumulation phase [2009_Beal]<ul> <li>burn-in: approximation is done on few samples per individual, and maximised and the process is repeated until the estimates have stabilised</li> <li>accumulation: the individual random-effects are sampled and averaged together</li> </ul> </li> </ul>"},{"location":"NLMEM/parameter_estimation/#imp","title":"IMP","text":"<ul> <li>IMPortance sampling</li> <li>[2007_Bauer]<ul> <li>step E: Monte-Carlo integration to assess the conditional mean and variance of \\(\u03b7_i\\)</li> <li>step M: maximises the expected likelihood</li> </ul> </li> <li>objective function is commonly generated by few iterations of IMP for the final parameter estimates.</li> </ul> <p>Note: [2014_Johansson] step E expectation evaluates the expected likelihood with respect to the conditional distribution of \\(\u03b7_i\\) based on the current parameter estimates and the observed data;  step M maximisation maximises the expected likelihood (from step E) to generate new parameter estimates.</p>"},{"location":"blog/","title":"Blog","text":""},{"location":"software/","title":"Description","text":"<p>This section highlights essential tools and methodologies for pharmacometric analysis, including:</p> <ul> <li>Key software and their applications in NLME modelling;</li> <li>Integration with R and R Studio;</li> <li>Python code</li> <li>markdown code implementations</li> </ul> <p>This document will serve as a resource for summarizing software functionalities, key references, and practical tips for documentation and pharmacometric analysis.</p>"},{"location":"software/markdown/","title":"Markdown","text":""},{"location":"software/markdown/#slideshow-of-figures","title":"Slideshow of figures","text":"<ul> <li> <p>Functionalities </p> <ul> <li>slide show</li> <li>height determines dimensions of the image</li> <li>1.8x zoom-in by clicking <ul> <li>can be changed in <code>transform: scale(1.8)</code></li> </ul> </li> <li>dimmed overlay<ul> <li>to dim everything around figure when zoomed in</li> </ul> </li> </ul> </li> <li> <p>the slideshow functionality across multiple markdown files in GitHub Pages</p> <ul> <li>use CSS code </li> <li>use JavaScript code</li> <li>combine both in markdown file</li> </ul> </li> </ul>"},{"location":"software/markdown/#css-code-for-slideshow","title":"CSS code for slideshow","text":"<ul> <li>the code used in .../docs/javascripts/extra.css</li> </ul> <pre><code>/* Container for the entire slideshow */\n.slideshow-container {\n    max-width: 800px;\n    min-width: 450px;\n    position: relative;\n    margin: auto;\n}\n\n/* Hide all slides by default */\n.mySlides {\n    display: none;\n}\n\n/* Container for each image to standardize dimensions */\n.image-container {\n    width: 100%;\n    height: 300px;\n    overflow: visible; /* Allow overflow for zoom effect */\n    position: relative;\n    max-width: 800px;\n    min-width: 450px;\n}\n\n/* Image styling for proper fit and zoom effect */\n.image-container img {\n    width: 100%;\n    height: 100%;\n    object-fit: contain; /* Ensure the entire image is visible within the container */\n    transition: transform 0.2s ease-in-out;\n}\n\n/* Navigation buttons */\n.prev, .next {\n    cursor: pointer;\n    position: absolute;\n    top: 0;\n    width: auto;\n    height: 100%;\n    padding: 16px;\n    color: white;\n    font-weight: bold;\n    font-size: 18px;\n    transition: 0.6s ease;\n    user-select: none;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n}\n\n/* Position the \"next\" button on the right */\n.next {\n    right: 0;\n    border-radius: 3px 0 0 3px;\n}\n\n/* Border radius for \"prev\" button */\n.prev {\n    border-radius: 0 3px 3px 0;\n}\n\n/* Hover effects for navigation buttons */\n.prev:hover, .next:hover {\n    background-color: rgba(0, 0, 0, 0.8);\n}\n\n/* Caption styling */\n.caption {\n    text-align: center;\n    color: #f2f2f2;\n    padding: 8px 12px;\n    background-color: rgba(0, 0, 0, 0.8);\n    position: absolute;\n    bottom: 0;\n    width: 100%;\n}\n\n/* Styles for zoom effect */\n.zoom {\n    cursor: zoom-in;\n}\n.zoomed {\n    transform: scale(2);\n    cursor: zoom-out;\n    position: relative;\n    z-index: 10; /* Ensure zoomed image is above other elements */\n}\n\n/* Dimmed overlay */\n.dimmed-overlay {\n    position: fixed;\n    top: 0;\n    left: 0;\n    width: 100%;\n    height: 100%;\n    background-color: rgba(0, 0, 0, 0.5); /* Adjust the opacity as needed */\n    z-index: 9; /* Ensure the overlay is below the zoomed image */\n    pointer-events: none; /* Allow interaction with elements behind the overlay */\n}\n\n.dimmed-overlay.zoomed {\n    display: none; /* Hide the overlay when an image is zoomed */\n}\n</code></pre>"},{"location":"software/markdown/#javascript-code-for-slideshow","title":"JavaScript code for slideshow","text":"<ul> <li>the code used in .../docs/javascripts/custom.js</li> </ul> <pre><code>// Initialize slide indices for multiple slideshows\nvar slideIndices = {};\n\n// Function to change slides\nfunction plusSlides(n, slideshowId) {\n    showSlides(slideIndices[slideshowId] += n, slideshowId);\n}\n\n// Function to show a specific slide\nfunction currentSlide(n, slideshowId) {\n    showSlides(slideIndices[slideshowId] = n, slideshowId);\n}\n\n// Main function to display slides\nfunction showSlides(n, slideshowId) {\n    var i;\n    var slideshow = document.getElementById(slideshowId);\n    var slides = slideshow.getElementsByClassName(\"mySlides\");\n    if (n &gt; slides.length) { // Wrap around to the first slide\n        slideIndices[slideshowId] = 1;\n    }\n    if (n &lt; 1) { // Wrap around to the last slide\n        slideIndices[slideshowId] = slides.length;\n    }\n    for (i = 0; i &lt; slides.length; i++) { // Hide all slides\n        slides[i].style.display = \"none\";\n    }\n    slides[slideIndices[slideshowId] - 1].style.display = \"block\"; // Show the current slide\n}\n\n// Initial setup for each slideshow\ndocument.addEventListener(\"DOMContentLoaded\", function() {\n    document.querySelectorAll('.slideshow-container').forEach(container =&gt; {\n        var id = container.id;\n        slideIndices[id] = 1;\n        showSlides(1, id);\n    });\n\n    // Zoom functionality for images\n    document.querySelectorAll('.zoom').forEach(img =&gt; {\n        img.addEventListener('click', function() {\n            if (this.classList.contains('zoomed')) {\n                this.classList.remove('zoomed'); // Remove zoom\n                document.getElementById('dimmed-overlay').remove(); // Remove dimmed overlay\n            } else {\n                this.classList.add('zoomed'); // Add zoom\n                const overlay = document.createElement('div');\n                overlay.classList.add('dimmed-overlay');\n                overlay.id = 'dimmed-overlay';\n                document.body.appendChild(overlay); // Add dimmed overlay\n            }\n        });\n    });\n\n    // Add captions based on file names\n    document.querySelectorAll('.image-container').forEach(container =&gt; {\n        const img = container.querySelector('img');\n        const caption = container.querySelector('.caption');\n        const fileName = img.src.split('/').pop().split('.')[0]; // Extract file name\n        caption.innerText = fileName.replace(/_/g, ' '); // Set caption text\n    });\n});\n</code></pre>"},{"location":"software/markdown/#linking-in-markdown-file","title":"Linking in Markdown file","text":"<ul> <li>the code used in any markdown file (.md) within Github Pages<ul> <li>change <code>slideshow_i</code> with slideshow number for separate slidesshows (e.g. slideshow_1, slideshow_2)</li> <li>change <code>slide_i</code> with path/link to image</li> <li>change <code>...</code> with path to your main GitHub repository </li> </ul> </li> </ul> <pre><code>#### Slideshow i\n&lt;div class=\"slideshow-container\" id=\"slideshow_i\"&gt;\n    &lt;div class=\"mySlides\"&gt;\n        &lt;div class=\"image-container\"&gt;\n            &lt;img src=\"image_i\" class=\"zoom\"&gt;\n            &lt;div class=\"caption\"&gt;&lt;/div&gt;\n        &lt;/div&gt;\n    &lt;/div&gt;\n    &lt;a class=\"prev\" onclick=\"plusSlides(-1, 'slideshow_i')\"&gt;\u276e&lt;/a&gt;\n    &lt;a class=\"next\" onclick=\"plusSlides(1, 'slideshow_i')\"&gt;\u276f&lt;/a&gt;\n&lt;/div&gt;\n\n*Caption for Slideshow*\n\n&lt;link rel=\"stylesheet\" href=\".../docs/stylesheets/extra.css\"&gt;\n&lt;script src=\".../docs/javascripts/custom.js\"&gt;&lt;/script&gt;\n</code></pre>"},{"location":"software/markdown/#demonstration","title":"Demonstration","text":""},{"location":"software/markdown/#slideshow-1","title":"Slideshow 1","text":"\u276e \u276f <p>Images were adopted from Matt Might. \"The illustrated guide to a Ph.D.\" \ud83d\udd17</p>"},{"location":"software/markdown/#slideshow-2","title":"Slideshow 2","text":"\u276e \u276f <p>Comics were adopted from Jorge Cham. \"The 200 Most Popular Comics\" \ud83d\udd17</p> <p></p>"},{"location":"software/markdown/#3dmoljs","title":"3Dmol.js","text":""},{"location":"software/markdown/#description","title":"Description","text":"<ul> <li>3D molecular visualization tool for web browsers.</li> <li>Interactive: Real-time manipulation (rotate, zoom).</li> <li>Customizable: Supports various rendering styles (stick, sphere, cartoon) and color schemes.</li> <li>Ease of Use: Simple JavaScript API for web developers.</li> <li>Ideal for embedding in web pages and applications.</li> <li> <p>Open Source 3Dmol.js GitHub webpage</p> </li> <li> <p>Ideas for the future:</p> <ul> <li>synchronised view</li> </ul> </li> </ul>"},{"location":"software/markdown/#demonstration_1","title":"Demonstration","text":""},{"location":"software/markdown/#example-1-caffeine","title":"Example 1: Caffeine","text":"<ul> <li>input</li> </ul> <pre><code>&lt;center&gt;\n  &lt;div \n    style=\"height: 450px; width: 90%; position: relative;\" \n    class='viewer_3Dmoljs' \n    data-cid='2519' \n    data-backgroundcolor='0xffffff' \n    data-style='stick:colorscheme=cyanCarbon' \n    data-ui='true'&gt;\n  &lt;/div&gt;\n&lt;/center&gt;\n\n&lt;script src=\"https://3Dmol.org/build/3Dmol-min.js\"&gt;&lt;/script&gt;     \n&lt;script src=\"https://3Dmol.org/build/3Dmol.ui-min.js\"&gt;&lt;/script&gt;  \n</code></pre> <ul> <li>Output</li> </ul> <p> <p></p> <p>Structure of caffeine. \"CID:2519\" \ud83d\udd17</p>"},{"location":"software/markdown/#example-2-human-a2a-adenosine-receptor","title":"Example 2: Human A2A Adenosine Receptor","text":"<ul> <li>Input</li> </ul> <p><pre><code>&lt;center&gt;\n  &lt;div \n    style=\"height: 450px; width: 90%; position: relative;\" \n    class='viewer_3Dmoljs' \n    data-pdb='3EML' \n    data-backgroundcolor='0xffffff' \n    data-style='stick:colorscheme=cyanCarbon'&gt;\n  &lt;/div&gt;\n&lt;/center&gt;\n\n&lt;center&gt;\n  &lt;div \n    style=\"height: 450px; width: 90%; position: relative;\" \n    class='viewer_3Dmoljs' \n    data-pdb='3EML' \n    data-backgroundcolor='0xffffff' \n    data-style='cartoon:color=spectrum' \n    data-surface='opacity:.5'&gt;\n  &lt;/div&gt;\n&lt;/center&gt;\n\n&lt;script src=\"https://3Dmol.org/build/3Dmol-min.js\"&gt;&lt;/script&gt;     \n&lt;script src=\"https://3Dmol.org/build/3Dmol.ui-min.js\"&gt;&lt;/script&gt;  \n</code></pre> * Output</p> <p> <p></p> <p> <p></p> <p>Structure of Human A2A Adenosine Receptor bound to ZM241385. It is antagonized by caffeine. \"PDB:3EML\" \ud83d\udd17</p>"},{"location":"software/markdown/#example-3-human-a2a-adenosine-receptor","title":"Example 3: Human A2A Adenosine Receptor","text":"<ul> <li>Input</li> </ul> <p><pre><code>&lt;center&gt;\n  &lt;div \n    style=\"height: 450px; width: 90%; position: relative;\" \n    class='viewer_3Dmoljs' \n    data-pdb='6J5T' \n    data-backgroundcolor='0xffffff'\n    data-style='cartoon:color=black'\n    data-select1='chain:A,D,I,J,M' data-style1='cartoon:color=#69BE28'\n    data-select2='chain:B,E,H,K,N' data-style2='cartoon:color=#FF8849'\n    data-select3='chain:C,F,G,L,O' data-style3='cartoon:color=#3DB7E4'     \n    data-surface='opacity:.4;color:0xffffff'&gt;\n  &lt;/div&gt;\n&lt;/center&gt;\n\n&lt;script src=\"https://3Dmol.org/build/3Dmol-min.js\"&gt;&lt;/script&gt;     \n&lt;script src=\"https://3Dmol.org/build/3Dmol.ui-min.js\"&gt;&lt;/script&gt;  \n</code></pre> * Output</p> <p> <p></p> <p>Structure of of a plant NLR resistosome. An immune system machines that play role in protection of plants from infection. \"PDB:6J5T; MW of 924 kDa\" \ud83d\udd17</p> <pre><code>\n</code></pre> <pre><code>\n</code></pre>"},{"location":"software/nonmem/","title":"NONMEM","text":"<ul> <li>NLME models</li> </ul>"},{"location":"software/nonmem/#installation-in-macos","title":"Installation in macOS","text":"<ul> <li>the material is based on readme_751_MACOSX.txt file from NONMEM webpage</li> <li>It worked with my MacBook (M3) with macOS Sonoma 14.5</li> <li>You'll need:<ul> <li>password to open zip file</li> <li>licence file</li> </ul> </li> </ul>"},{"location":"software/nonmem/#command-line-tools","title":"Command Line Tools","text":"<ul> <li>Install newest Command Line Tools in Mac OS  <pre><code># uninstall older versions\nsudo rm -rf /Library/Developer/CommandLineTools\n# install new version\nxcode-select --install\n</code></pre></li> </ul>"},{"location":"software/nonmem/#gfortran","title":"gfortran","text":"<ul> <li> <p>Install gfortran using homebrew <pre><code># install homebrew\n/bin/bash -c \"$(curl -fsSL https://raw.githubusercontent.com/Homebrew/install/HEAD/install.sh)\"\n\n# add `/opt/homebrew/bin` (or your homebrew path) to your PATH\n## for .zsh. (if you use bash, `nano ~/.bash_profile`)\nnano ~/.zshrc\n        ## add this in the file, save changes and exit `\u2303 + O, \u2303 + X`.\n        export PATH=\"/opt/homebrew/bin:$PATH\"\n## apply the changes. (if you use bash, `source ~/.bash_profile`)\nsource ~/.zshrc\n## verify changes (homebrew path should be in listed paths)\necho $PATH\n\n# install gcc\nbrew install gcc\n\n# Add symbolic link to gcc\n## use if it is not there\nmkdir -p ~/bin\n## version number might change\nln -sf /opt/homebrew/bin/gcc-14 ~/bin/gcc\n\n# check versions \n##to ensure that it won't use the \"clang\" C compiler\nexport PATH=/usr/local/bin:/usr/local/gfortran/bin:$PATH\n##gcc and GNU Fortran versions should match\ngcc --version\ngfortran --version\n</code></pre></p> </li> <li> <p>Compiler Test for Fortran</p> </li> </ul> <pre><code># Create the `Compiler/test` Directory\nmkdir -p ~/Compiler/test\ncd ~/Compiler/test\n\n# Create the Fortran Source File\n## create and open file\nnano hello.f90\n        ## add this in the file, save changes and exit `\u2303 + O, \u2303 + X`.\n        program hello\n            print *, 'Hello, NONMEM World!'\n        end program hello\n\n# Create the Makefile\n## create and open file\nnano Makefile\n        ## add this in the file, save changes and exit `\u2303 + O, \u2303 + X`.\n        FC = gfortran\n        FFLAGS = -O2\n        TARGET = hello\n\n        all: $(TARGET)\n\n        $(TARGET): $(TARGET).o\n            $(FC) $(FFLAGS) -o $(TARGET) $(TARGET).o\n\n        $(TARGET).o: $(TARGET).f90\n            $(FC) $(FFLAGS) -c $(TARGET).f90\n\n        clean:\n            rm -f $(TARGET) $(TARGET).o\n\n# Run the Make Commands\nmake clean\nmake\n./hello\n## Uutput: `Hello, NONMEM`\n\n# remove created folder\nrm -rf ~/Compiler\n</code></pre>"},{"location":"software/nonmem/#install-nonmem","title":"Install NONMEM","text":"<ul> <li>download installation files from NONMEM webpage</li> </ul> <pre><code># Unzip zip file in terminal (you'll need password from ICON).\nunzip Downloads/NONMEM751.zip\ncd Downloads/nm751CD  \n\n# Remove extra attributes\nxattr -rc nm751CD \n\n# install nonmem\nsudo /bin/bash SETUP75 ~/Downloads/nonmem751/nm751CD /opt/NONMEM/nm751 gfortran y ar same rec i\n\n# executes the NONMEM script\ncd /opt/NONMEM/nm751/run\n./nmfe75 CONTROL5 REPORT5.txt -prdefault\nls -l prsame.set\n\n# add symbolic links and aliases\nln -sf /opt/NONMEM/nm751/run/nmfe75 ~/bin/nmfe75\nln -sf /opt/NONMEM/nm751/run/nmfe75 ~/bin/nmfe                \nln -sf /opt/NONMEM/nm751/help/nmhelp ~/bin/nmhelp\nalias nmhelp_web='open /opt/NONMEM/nm751/html/index.htm'\n</code></pre>"},{"location":"software/nonmem/#update-licence-file","title":"Update licence file","text":"<ul> <li>it should be located in <code>/opt/NONMEM/nm751/license/nonmem.lic</code></li> </ul>"},{"location":"software/pirana/","title":"Pirana","text":"<ul> <li>[ref]</li> <li>graphical user interface </li> <li>enables an easier documentation of models and the modelling process</li> </ul>"},{"location":"software/psn/","title":"PsN","text":"<ul> <li>Perl speaks NONMEM</li> <li>[ref]</li> <li>tool to ease the model development</li> <li>bootstrap </li> <li>Case-deletion diagnostics</li> <li>log-likelihood profiling</li> </ul>"},{"location":"software/psn/#installation-in-macbook","title":"Installation in MacBook","text":"<ul> <li>the material is based on documentation from PsN webpage</li> <li>It worked with my MacBook (M3) with macOS Sonoma 14.5</li> <li>You'll need:<ul> <li>working NONMEM </li> </ul> </li> </ul>"},{"location":"software/psn/#check-for-required-software","title":"Check for required software","text":"<pre><code># Homebrew \n## Display Homebrew prefix path\nbrew --prefix\nbrew list --versions\n## Add Homebrew binary directory to PATH\nexport PATH=/opt/homebrew/bin:$PATH \nexport HOMEBREW_PREFIX=/opt/homebrew\n## Open the .zshrc file for editing\nnano ~/.zshrc \n        ## add this in the file, save changes and exit `\u2303 + O, \u2303 + X`.\n        export PATH=\"/opt/homebrew/bin:$PATH\"\n## Apply the changes made to .zshrc\nsource ~/.zshrc  \n\n# Perl \n## Install using Homebrew\nbrew install perl\n## Link Perl to make it accessible system-wide\nbrew link perl\n## Check Perl version\nperl -v\n## Verify the location of Perl executable\nwhich perl\n\n# Python\n## Check version\npython --version\npython3 --version\n\n# R \n## Check version\nR --version\n\n# Java\n## Check version\njava -version\n## Install if needed \n\n# Pandoc\n## Install Pandoc using Homebrew\nbrew install pandoc\n## Check Pandoc version\npandoc --version\n</code></pre>"},{"location":"software/psn/#system-dependencies","title":"System dependencies","text":"<ul> <li>for plotting and reporting</li> </ul> <pre><code># Install system dependencies for plotting and reporting using Homebrew\nbrew install openssl@1.1\nbrew install cairo\nbrew install mariadb-connector-c\n</code></pre>"},{"location":"software/psn/#perl-modules","title":"Perl modules","text":"<pre><code># Install Perl modules using CPAN\ncpan -f Math::Random\ncpan Math::MatrixReal\ncpan Mouse\ncpan MouseX::Params::Validate\ncpan Archive::Zip\ncpan YAML\ncpan Capture::Tiny\ncpan File::Copy::Recursive\ncpan File::HomeDir\ncpan Math::SigFigs\ncpan Statistics::Distributions\n</code></pre>"},{"location":"software/psn/#install-psn-531","title":"Install PsN 5.3.1","text":"<ul> <li>installltion files can be found in [PsN documentation]</li> <li>PsN 5.3.1.tar.gz file for macOS</li> </ul> <pre><code># Run the setup script for PsN in PsN-Source folder\nsudo perl setup.pl\n\n# Configuration file\n## Find the location of psn.conf configuration file \n## in my case it was in `/Library/Perl/5.34/PsN_5_3_1`\nsudo find / -name \"psn.conf\" 2&gt;/dev/null \n## Verify the content of  PsN configuration file\n        [nm_versions]\n        default=/opt/NONMEM/nm751,7.5\n        nm751=/opt/NONMEM/nm751,7.5\n        nonmem_nm751=/opt/nonmem/nm751,7.5\n## Display help information for PsN\npsn -help\n</code></pre>"},{"location":"software/psn/#extra","title":"Extra","text":"<ul> <li>Lines of code that helped to run PsN commands</li> </ul> <pre><code># Change ownership of Homebrew directory to the current user\nsudo chown -R {YOUR USERNAME} /opt/homebrew\n# Update Homebrew to the latest version\nbrew update\n# Upgrade all outdated Homebrew packages\nbrew upgrade\n# Clean up old versions of installed packages\nbrew cleanup\n# Reinstall GCC to ensure it's up-to-date\nbrew reinstall gcc\n# List GCC installation details\nbrew list gcc\n# Check if the libgfortran library is present\nls /opt/homebrew/opt/gcc/lib/gcc/current/libgfortran.5.dylib\n# Set DYLD_LIBRARY_PATH to include the GCC library path\nDYLD_LIBRARY_PATH=/opt/homebrew/opt/gcc/lib/gcc/current:$DYLD_LIBRARY_PATH\n# Apply the updated environment variables\nsource ~/.zshrc \n</code></pre>"},{"location":"software/python/","title":"Python code","text":""},{"location":"software/python/#py3dmol","title":"py3Dmol","text":""},{"location":"software/python/#description","title":"Description","text":"<ul> <li>To visualize molecular structures in 3D.</li> <li>Interactive: Real-time manipulation (rotate, zoom).</li> <li>Customizable: Various styles (stick, sphere, cartoon) and colors.</li> <li>Ease of Use: Simple API for Python users.</li> <li>Ideal for Jupyter Notebooks.</li> <li>Open Source [py3Dmol GitHub webpage]</li> </ul>"},{"location":"software/python/#examples","title":"Examples","text":""},{"location":"software/python/#example-1-cortisol-input","title":"Example 1 (cortisol) input","text":"<pre><code>#cortisol\nimport py3Dmol\n\nview = py3Dmol.view(query='cid:5754')\n\nview.setStyle({'stick': {'color':'spectrum'}})\nview.zoomTo()\nview.render()\n</code></pre>"},{"location":"software/python/#example-1-cortisol-output","title":"Example 1 (cortisol) output","text":""},{"location":"software/python/#example-2-cbg-input","title":"Example 2 (CBG) input","text":"<pre><code># CBG\nimport py3Dmol\n\nview = py3Dmol.view(width=800, height=800, query='pdb:2V95', viewergrid=(2,2), linked=True)\n\nview.setStyle({'cartoon': {'color': 'spectrum'}}, viewer=(0,0))\n\nview.setStyle({'cartoon': {'color': '#4aa6ff', 'style': 'parabola'}}, viewer=(0,1))\n\nview.addSurface(py3Dmol.VDW, {'opacity': 0.5}, viewer=(0,0))\nview.setStyle({'cartoon': {'color': 'spectrum'}}, viewer=(1,0))\nview.setStyle({'elem': 'Zn'}, {'sphere': {'scale': 2.0}}, viewer=(1,0))\nview.setStyle({'stick': {'colorscheme': 'cyanCarbon'}}, viewer=(1,1))\n\n\nview.setBackgroundColor('#ebf4fb', viewer=(0,0))\nview.setBackgroundColor('#ebf4fb', viewer=(0,1))\nview.setBackgroundColor('#ebf4fb', viewer=(1,0))\nview.setBackgroundColor('#ebf4fb', viewer=(1,1))\n\nview.zoomTo()\nview.render()\n</code></pre>"},{"location":"software/python/#example-2-cbg-output","title":"Example 2 (CBG) output","text":""},{"location":"software/r_studio/","title":"R and R studio","text":""},{"location":"software/r_studio/#ggplot2","title":"ggplot2","text":"<ul> <li>[ref] </li> <li>[ref]</li> </ul>"},{"location":"software/r_studio/#xpose4","title":"Xpose4","text":"<ul> <li>[ref]</li> </ul>"},{"location":"software/r_studio/#vpc","title":"VPC","text":"<ul> <li>[ref]</li> </ul>"},{"location":"software/r_studio/#personal-use","title":"Personal use","text":""},{"location":"software/r_studio/#packages","title":"Packages","text":""},{"location":"software/r_studio/#binom","title":"Binom","text":"<ul> <li>Uses eight different methods to obtain a confidence interval on the binomial probability.</li> <li>Example: 5 successes out of 100 independent trials with 95% of confidence in the binomial experiment</li> <li>Input </li> </ul> <pre><code>library(binom)\nbinom.confint(5, 100, conf.level = 0.95, Method = \"all\")\n</code></pre> <ul> <li>Output</li> </ul> Method Description Successes Trials Mean Lower Upper Agresti-Coull Agresti-Coull method 5 100 0.05000000 0.018676359 0.11461779 Asymptotic Using the Central Limit Theorem 5 100 0.05000000 0.007283575 0.09271642 Bayes Using Bayesian inference 5 100 0.05445545 0.015338169 0.09900926 Cloglog Using the complementary log parameterization 5 100 0.05000000 0.018604802 0.10514408 Exact Pearson-Klopper method 5 100 0.05000000 0.016431879 0.11283491 Logit Using the logistic parameterization 5 100 0.05000000 0.020964608 0.11454379 Probit Using the probit parameterization 5 100 0.05000000 0.019745646 0.10922194 Profile Using the profile likelihood 5 100 0.05000000 0.018242887 0.10439789 LRT 5 100 0.05000000 0.018250112 0.10439673 Prop.test 5 100 0.05000000 0.018552564 0.11829946 Wilson Wilson method 5 100 0.05000000 0.021543679 0.11175047"},{"location":"software/r_studio/#functions","title":"Functions","text":""},{"location":"software/r_studio/#leave","title":"leave()","text":"<ul> <li>Remove all objects except:<ul> <li>functions</li> <li>objects that contain specified string within their name</li> </ul> </li> <li>I just find it easier than writing every object in <code>rm()</code></li> </ul> <pre><code> leave &lt;- function(exclude_strings) {\n  # Get all objects in the global environment\n  all_objects &lt;- ls(envir = .GlobalEnv)\n\n  # Identify functions and objects containing specified strings in their names\n  functions &lt;- all_objects[sapply(all_objects, function(x) is.function(get(x)))]\n  exclude_objects &lt;- all_objects[sapply(all_objects, function(x) any(sapply(exclude_strings, function(s) grepl(s, x))))]\n\n  # Remove all objects except functions and objects containing specified strings in their names\n  objects_to_remove &lt;- setdiff(all_objects, c(functions, exclude_objects))\n  rm(list = objects_to_remove, envir = .GlobalEnv)\n}\n</code></pre>"},{"location":"software/r_studio/#plotsave","title":"plotsave()","text":"<ul> <li>save all objects that are named as <code>str</code>+<code>i</code> (e.g. plot1, plot_1 or p1) in <code>path</code> (path specified folder)<ul> <li>the folder will be created if it doesn't exist</li> </ul> </li> </ul> <pre><code>plotsave &lt;- function(path, str) {\n  for (i in 1:30) {\n    tryCatch({\n      plot_object &lt;- get(paste0(str, i))\n    if (!is.null(plot_object)) {\n      plot_name &lt;- paste0(path, \"plot\", i, \".png\")\n      ggsave(plot_name, plot = plot_object, width = 6, height = 4.5, units = \"in\", dpi = 300, create.dir = TRUE)\n    }}, error = function(e) {})\n  }\n}\n</code></pre>"},{"location":"software/r_studio/#theme_custom","title":"theme_custom()","text":"<ul> <li>Custom ggplot2 theme that can be re-used <ul> <li>if there are additional changes it can be added in <code>...</code></li> </ul> </li> </ul> <pre><code>theme_custom &lt;- function(...) {\n  theme_bw()+\n  theme(\n          legend.text  = element_text(size = 6),\n          axis.text.x  = element_text(size = 6, angle = 0, vjust = 0, hjust=0.5),\n          axis.text.y  = element_text(size = 6),\n          plot.caption = element_text(size = 6, hjust = 0),\n          legend.title = element_text(size = 8, face=\"bold\"),\n          axis.title.y = element_text(size = 8, face=\"bold\"),\n          axis.title.x = element_text(size = 8, face=\"bold\"),\n          strip.text.x = element_text(size = 8, face=\"bold\"),\n          title = element_text(size = 10, face=\"bold\")\n        ) +\n    theme(...)\n}\n</code></pre>"},{"location":"software/terminal/","title":"Terminal","text":""},{"location":"software/terminal/#commands","title":"Commands","text":""},{"location":"software/terminal/#_1","title":"Terminal","text":""}]}